Last reviewed · How we verify
Colforsin Dapropate — Competitive Intelligence Brief
unknown
Adenylate cyclase type 1, Adenylate cyclase type 8, Solute carrier family 2, facilitated glucose transporter member 1
Other
Live · refreshed every 30 min
Target snapshot
Colforsin Dapropate (colforsin daropate). Colforsin Dapropate works by activating adenylate cyclase type 1, which increases the production of cyclic AMP (cAMP) within cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Colforsin Dapropate TARGET | colforsin daropate | unknown | Adenylate cyclase type 1, Adenylate cyclase type 8, Solute carrier family 2, facilitated glucose transporter member 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Colforsin Dapropate CI watch — RSS
- Colforsin Dapropate CI watch — Atom
- Colforsin Dapropate CI watch — JSON
- Colforsin Dapropate alone — RSS
Cite this brief
Drug Landscape (2026). Colforsin Dapropate — Competitive Intelligence Brief. https://druglandscape.com/ci/colforsin-daropate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing